MX2023004920A - Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). - Google Patents
Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).Info
- Publication number
- MX2023004920A MX2023004920A MX2023004920A MX2023004920A MX2023004920A MX 2023004920 A MX2023004920 A MX 2023004920A MX 2023004920 A MX2023004920 A MX 2023004920A MX 2023004920 A MX2023004920 A MX 2023004920A MX 2023004920 A MX2023004920 A MX 2023004920A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- bcl6
- inhibitors
- compounds
- Prior art date
Links
- 229940096923 Bcl6 inhibitor Drugs 0.000 title 1
- 102000013538 Proto-Oncogene Proteins c-bcl-6 Human genes 0.000 abstract 3
- 108010090920 Proto-Oncogene Proteins c-bcl-6 Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula I que funcionan como inhibidores de la actividad de BCL6 (proteína 6 del linfoma de linfocitos B): (ver Fórmula) Fórmula I donde X1, R1, R2, R30, R31 y el Anillo A son cada uno tal como se definen en la presente. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento de trastornos proliferativos, tales como el cáncer, así como otras enfermedades o afecciones en las que interviene la actividad de BCL6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
| GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004920A true MX2023004920A (es) | 2023-05-16 |
Family
ID=66240166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010805A MX2020010805A (es) | 2018-04-13 | 2019-04-12 | Inhibidores de bcl6. |
| MX2023004920A MX2023004920A (es) | 2018-04-13 | 2020-10-12 | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010805A MX2020010805A (es) | 2018-04-13 | 2019-04-12 | Inhibidores de bcl6. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11512095B2 (es) |
| EP (2) | EP4201939A1 (es) |
| JP (1) | JP7493454B2 (es) |
| KR (1) | KR20200144109A (es) |
| CN (1) | CN112334475A (es) |
| AU (2) | AU2019253510B2 (es) |
| BR (1) | BR112020020832A2 (es) |
| CA (1) | CA3095371A1 (es) |
| DK (1) | DK3774817T3 (es) |
| ES (1) | ES2939776T3 (es) |
| HR (1) | HRP20230120T1 (es) |
| IL (2) | IL296734A (es) |
| MX (2) | MX2020010805A (es) |
| PT (1) | PT3774817T (es) |
| SG (1) | SG11202009735QA (es) |
| WO (1) | WO2019197842A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019197842A1 (en) * | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| US20220323457A1 (en) * | 2019-10-17 | 2022-10-13 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| CR20230516A (es) | 2021-04-16 | 2024-01-23 | Arvinas Operations Inc | Moduladores de la proteólisis bcl6 y métodos de uso asociados |
| TW202415665A (zh) | 2022-06-06 | 2024-04-16 | 美商樹線生物科學公司 | 三環喹啉酮ｂｃｌ６雙功能降解劑 |
| TW202415655A (zh) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑 |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| WO2024019995A1 (en) * | 2022-07-19 | 2024-01-25 | Dana-Farber Cancer Institute, Inc. | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
| EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| MXPA02011770A (es) | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| BRPI0915273B1 (pt) * | 2008-11-11 | 2021-08-03 | Je Il Pharmaceutical Co., Ltd | Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação |
| US9663494B2 (en) | 2013-03-05 | 2017-05-30 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| US9943506B2 (en) | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| US11001570B2 (en) * | 2016-12-13 | 2021-05-11 | Boehringer Ingelheim International Gmbh | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors |
| WO2018215801A1 (en) | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| EP4371562A2 (en) * | 2017-05-26 | 2024-05-22 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| WO2019197842A1 (en) * | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
-
2019
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en active Application Filing
- 2019-04-12 EP EP22211485.2A patent/EP4201939A1/en active Pending
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/hr unknown
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/pt unknown
- 2019-04-12 KR KR1020207032149A patent/KR20200144109A/ko not_active Application Discontinuation
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/ja active Active
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/es unknown
- 2019-04-12 ES ES19718834T patent/ES2939776T3/es active Active
- 2019-04-12 PT PT197188345T patent/PT3774817T/pt unknown
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/da active
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 IL IL296734A patent/IL296734A/en unknown
- 2019-04-12 CN CN201980039513.4A patent/CN112334475A/zh active Pending
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/es unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US20230287003A1/en active Pending
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200144109A (ko) | 2020-12-28 |
| CN112334475A (zh) | 2021-02-05 |
| JP7493454B2 (ja) | 2024-05-31 |
| EP4201939A1 (en) | 2023-06-28 |
| ES2939776T3 (es) | 2023-04-26 |
| MX2020010805A (es) | 2021-01-29 |
| IL277778B (en) | 2022-11-01 |
| SG11202009735QA (en) | 2020-10-29 |
| US20210163497A1 (en) | 2021-06-03 |
| US11512095B2 (en) | 2022-11-29 |
| BR112020020832A2 (pt) | 2021-01-19 |
| IL296734A (en) | 2022-11-01 |
| EP3774817A1 (en) | 2021-02-17 |
| HRP20230120T1 (hr) | 2023-06-09 |
| AU2019253510B2 (en) | 2023-08-10 |
| IL277778B2 (en) | 2023-03-01 |
| AU2019253510A1 (en) | 2020-10-22 |
| EP3774817B1 (en) | 2022-12-07 |
| WO2019197842A1 (en) | 2019-10-17 |
| PT3774817T (pt) | 2023-03-09 |
| DK3774817T3 (da) | 2023-02-13 |
| AU2023263501A1 (en) | 2023-11-30 |
| US20230287003A1 (en) | 2023-09-14 |
| CA3095371A1 (en) | 2019-10-17 |
| JP2021521165A (ja) | 2021-08-26 |
| IL277778A (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| CR20200312A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| MX2022006700A (es) | Compuestos poliheterociclicos como inhibidores de mettl3. | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| CR20220236A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
| CR20200584A (es) | Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
| MX2022004419A (es) | Derivados de [1,4]oxazepino[2,3c]quinolinona como inhibidores de bcl6. | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| BR112021026682A2 (pt) | Compostos e métodos para inibir eif4e | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
| PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors |